S K Imam1. 1. Department of Nuclear Medicine, Liverpool Hospital, Liverpool, Sydney, Australia. seyed.imam@swsahs.nsw.gov.au
Abstract
PURPOSE: This synopsis attempts to shed light on the progresses made in the field of cancer therapy using alpha-particles. HURDLES AND PROGRESSES: The rationale of selection of radionuclides focusing on comparison of alpha- and beta-emitters, the hurdles and their solutions, and recent developments are addressed. The efforts made in the field of alpha-radioimmunotherapy of hematologic malignancies are emphasized. A good deal of progress has been achieved in the past decade, and preclinical studies with a variety of radioimmunoconjugates with astatine and bismuth radioisotopes (At-211, Bi-212, and Bi-213) have generated encouraging results, providing an impetus for future clinical trials. CONCLUSION: The onset of early clinical trials with alpha-emitters will hopefully enable the cancer researchers to come up with extremely effective and highly specific "smart bombs" to target cancer cells.
PURPOSE: This synopsis attempts to shed light on the progresses made in the field of cancer therapy using alpha-particles. HURDLES AND PROGRESSES: The rationale of selection of radionuclides focusing on comparison of alpha- and beta-emitters, the hurdles and their solutions, and recent developments are addressed. The efforts made in the field of alpha-radioimmunotherapy of hematologic malignancies are emphasized. A good deal of progress has been achieved in the past decade, and preclinical studies with a variety of radioimmunoconjugates with astatine and bismuth radioisotopes (At-211, Bi-212, and Bi-213) have generated encouraging results, providing an impetus for future clinical trials. CONCLUSION: The onset of early clinical trials with alpha-emitters will hopefully enable the cancer researchers to come up with extremely effective and highly specific "smart bombs" to target cancer cells.
Authors: J Carlsson; Z P Ren; K Wester; A L Sundberg; N E Heldin; G Hesselager; M Persson; L Gedda; V Tolmachev; H Lundqvist; E Blomquist; M Nistér Journal: J Neurooncol Date: 2006-03 Impact factor: 4.130
Authors: Pinakin Sukthankar; L Adriana Avila; Susan K Whitaker; Takeo Iwamoto; Alfred Morgenstern; Christos Apostolidis; Ke Liu; Robert P Hanzlik; Ekaterina Dadachova; John M Tomich Journal: Biochim Biophys Acta Date: 2014-02-22
Authors: Brian W Miller; Sofia H L Frost; Shani L Frayo; Aimee L Kenoyer; Erlinda Santos; Jon C Jones; Damian J Green; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Johnnie J Orozco; Oliver W Press; John M Pagel; Brenda M Sandmaier Journal: Med Phys Date: 2015-07 Impact factor: 4.071